Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Minimal clinically important differences for the EQ-5D and QWB-SA in Post-traumatic Stress Disorder (PTSD): results from a Doubly Randomized Preference Trial (DRPT)

  NO-CHOICE (RANDOMIZATION)    CHOICE   TOTAL
  PE SER Subtotal PE SER Subtotal  
Number of Patients (%) 55 48 103 61 36 97 200
Age in years, mean (SD) 36.2 (11.4) 38.9 (11.3) 37.5 (11.4) 37.1 (11.3) 38.3 (11.4) 37.5 (11.3) 37.5 (11.3)
Gender (%)
   Female 78.2% 79.2% 78.6% 75.4% 69.4% 73.2% 76.0%
   Male 21.8% 20.8% 21.4% 24.6% 30.6% 26.8% 24.0%
Education (College Educated) (%) 38.2% 23.0% 31.1% 42.6% 22.2% 35.1% 33.0%
PTSD Severity (PSS-I), mean (SD) 29.7 (7.1) 29.6 (6.3) 29.7 (6.7) 29.1 (6.8) 30.0 (6.7) 29.5 (6.7) 29.6 (6.7)
   Re-experiencing, mean (SD) 7.8 (2.7) 7.5 (3.0) 7.7 (2.9) 7.3 (2.7) 7.5 (2.8) 7.4 (2.7) 7.5 (2.8)
   Avoidance, mean (SD) 12.3 (3.8) 11.9 (3.4) 12.1 (3.6) 12.2 (3.1) 12.4 (3.1) 12.3 (3.1) 12.2 (3.3)
   Hyperarousal, mean (SD) 9.6 (3.3) 10.2 (2.5) 9.9 (2.9) 9.6 (2.9) 10.1 (3.1) 9.8 (3.0) 9.8 (3.0)
CGI-S, mean (SD) 4.6 (1.0) 4.5 (0.9) 4.6 (1.0) 4.6 (1.1) 4.4 (0.9) 4.5 (1.0) 4.6 (1.0)
EQ-5D, mean (SD) 0.67 (0.18) 0.60 (0.21) 0.61 (0.20) 0.65 (0.17) 0.56 (0.19) 0.62 (0.18) 0.63 (0.19)
QWB-SA, mean (SD) 0.58 (0.11) 0.57 (0.10) 0.57 (0.11) 0.56 (0.10) 0.59 (0.11) 0.57 (0.10) 0.57 (0.11)
  1. SER, Pharmacotherapy with sertraline; PE, Prolonged Exposure Therapy; PTSD, Post-traumatic Stress Disorder; PSS-I, PTSD Symptom Scale-Interview; CGI-S, Clinical Global Impression-Severity; EQ-5D, EuroQol Group-5 Dimensions; QWB-SA, Quality of Well-Being-Self Administration.